FindMyRecallSubscribe
Class III: unlikely to cause harmOngoing

Orient Pharma Co., Ltd. Yunlin Plant Pitavastatin Tablets Recall

Pitavastatin Tablets, 2 mg, Rx Only, 90 Tablets, Manufactured by: Orient Pharma Co

Orient Pharma Co., Ltd. Yunlin Plant

Risk level
Class III
Reported by FDA
Jul 9, 2025
Recall ID
D-0526-2025
Check your lot numberHow we source this data

Summary

Orient Pharma Co., Ltd. Yunlin Plant recalled Pitavastatin Tablets starting Jun 11, 2025. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0526-2025 on Jul 9, 2025. Reason: Failed Impurities/Degradation Specifications. Status: Ongoing.

Why it was recalled

Failed Impurities/Degradation Specifications.

Product description

Pitavastatin Tablets, 2 mg, Rx Only, 90 Tablets, Manufactured by: Orient Pharma Co., Ltd., 8 Kehu 1st Road, Huwei Chen, Yunlin, Taiwan, 63247, Manufactured for: Teva Pharmaceuticals, Parsippany, NJ 07054, Product of Taiwan, NDC 0480-3632-98.

Lot numbers, UPCs & expiration codes

P061001, P061002, P061003, P061004, P061006 & P061007 Exp Date 07/2025; P061008, Exp Date 08/2025; P061009 & P061010 Exp Date 10/2025; P061011, P061012 & P061013 Exp Date 01/2026; P061016, P061017 & P061018, Exp Date 04/2026; P061019, Exp Date 05/2026; P061023, Exp Date 01/2027.

Where it was sold

NJ

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0526-2025
Classification
Class III
Status
Ongoing
Recall initiated
Jun 11, 2025
FDA report date
Jul 9, 2025
Quantity
57504 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Orient Pharma Co., Ltd. Yunlin Plant

Original FDA data

Every field from FDA enforcement report D-0526-2025, exactly as published.

Show all FDA fields
City
Yunlin County
Status
Ongoing
Country
Taiwan
Event ID
97076
Address
No. 8 Kehu 1st Rd.
Address (line 2)
Huwei Township
Code information
P061001, P061002, P061003, P061004, P061006 & P061007 Exp Date 07/2025; P061008, Exp Date 08/2025; P061009 & P061010 Exp Date 10/2025; P061011, P061012 & P061013 Exp Date 01/2026; P061016, P061017 & P061018, Exp Date 04/2026; P061019, Exp Date 05/2026; P061023, Exp Date 01/2027.
Report date
Jul 9, 2025
Product type
Drugs
Recall number
D-0526-2025
Classification
Class III
Recalling firm
Orient Pharma Co., Ltd. Yunlin Plant
Product quantity
57504 bottles
Reason for recall
Failed Impurities/Degradation Specifications.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Pitavastatin Tablets, 2 mg, Rx Only, 90 Tablets, Manufactured by: Orient Pharma Co., Ltd., 8 Kehu 1st Road, Huwei Chen, Yunlin, Taiwan, 63247, Manufactured for: Teva Pharmaceuticals, Parsippany, NJ 07054, Product of Taiwan, NDC 0480-3632-98.
Distribution pattern
NJ
Recall initiation date
Jun 11, 2025
Initial firm notification
Letter
Center classification date
Jul 16, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0526-2025, published Jul 9, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls